Who are the PDCO?

Area of Science:

• Pharmacovigilance
• Pediatric Medicine
• Regulatory Science

Background:

• The Paediatric Regulation, effective January 2007, established the European Medicines Agency's Paediatric Committee (PDCO).
• The PDCO aims to enhance pediatric medicine research and development within the European Union.
• Medicines are often used off-label in children, necessitating dedicated research and regulatory pathways.

Purpose of the Study:

• To summarize the establishment and goals of the Paediatric Committee (PDCO).
• To highlight the role of the PDCO in authorizing Paediatric Investigation Plans and Paediatric Use Marketing Authorisations.
• To discuss the impact of the EU's Seventh Framework Programme in fostering research consortia for pediatric medicines.

Main Methods:

• The Paediatric Regulation established the PDCO.
• The Seventh Framework Programme facilitated research consortia.
• Consortia aim to answer clinical questions regarding pediatric medicine use.

Main Results:

• The PDCO's major functions include formulating and authorizing Paediatric Investigation Plans and Paediatric Use Marketing Authorisations.
• Research consortia enhance collaboration among pediatricians, scientists, and SMEs.
• These collaborations aim to secure authorization for new pediatric medicine indications or formulations.

Conclusions:

• The Paediatric Regulation and PDCO represent a significant European initiative to improve pediatric medicine.
• Research consortia are a key mechanism for addressing unmet needs in pediatric pharmacotherapy.
• The long-term success of this initiative in optimizing pediatric medicine use will be evaluated over time.